Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label adalimumab extension in pediatric ulcerative colitis after M11-290
2015-001346-29Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Sep 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of adalimumab in autoimmune colitis, sponsored by AbbVie Inc. Primary endpoint: Efficacy assessment using PMS, Mayo score, and PUCAI. Started Sep 2015; status: completed.
02
Drugs
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2015-001346-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001346-29.